Study to Assess Effectiveness and Safety of Zanubrutinib for Patients With Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)

ConditionMarginal Zone Lymphoma(MZL)

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorIRCCS Azienda Ospedaliero-Universitaria di Bologna

About this trial

Observational, non-interventional, retrospective, multicentre study focusing on efficacy and safety of zanubrutinib in daily clinical practice in patients with relapsed/refractory (R/R) marginal zone lymphoma.

Eligibility criteria

Qualifiers

Histologically confirmed diagnosis of relapsed/refractory marginal zone lymphoma

Patients who received at least one dose of zanubrutinib under the Named patient program (D.M. 7 Sep 2017), between January 2021 and October 2023 3) Age≥18 at start of zanubrutinib therapy. 4) Signature of written informed consent to study participation and personal data processing.

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Locations15

Select a site below to view it on the map.

Sponsors and collaborators

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Lead sponsor

Source ClinicalTrials.gov